Skip to content
Disclosery

REGENERON PHARMACEUTICALS, INC.

Follow

13F filer, CIK 872589, TARRYTOWN, NY

REGENERON PHARMACEUTICALS, INC. reported $33,799,428 across 2 holdings for the quarter ended 2025-12-31, in a 13F-HR filed 2026-02-06.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001104659-26-011601

Period
2025-12-31
Reported value
$33.8M
Holdings
2
Top 10 weight
100%
New
0
Sold out
2

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
ALNYexited-1,392,303-$635M
ADICET BIO INCreduced-907,672-$7.64M
ADVERUM BIOTECHNOLOGIES INCexited-180,909-$820K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q4 2025

Share positions as resolved from 13F-HR 0001104659-26-011601, largest first. % of portfolio is the value over $33,799,428, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
NTLAINTELLIA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 3,702,995 shares; 2025Q1: 3,702,995 shares; 2025Q2: 3,702,995 shares; 2025Q3: 3,702,995 shares; 2025Q4: 3,702,995 shares 3,702,995$33.3M98.49%0Timeline
ADICET BIO INCADICET BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 968,183 shares; 2025Q1: 968,183 shares; 2025Q2: 968,183 shares; 2025Q3: 968,183 shares; 2025Q4: 60,511 shares 60,511$510K1.51%-907,672

Sold out in Q4 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
ALNYALNYLAM PHARMACEUTICALS INC1,392,303$635Mshares
ADVERUM BIOTECHNOLOGIES INCADVERUM BIOTECHNOLOGIES INC180,909$820Kshares

How Q4 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001104659-26-011601 base2026-02-06acceptance time not in the bulk data set